BeyondSpring Inc.
BYSI Healthcare Biotechnology
In the quarter to June 2026, EPS grew 50.0% and free cash flow grew 35.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow BYSI
BeyondSpring Inc. (BYSI) EV/Sales
As of 16 October 2026, BeyondSpring Inc. (BYSI) trades at a EV/Sales of 13.8×. Over the past ten years it has ranged from −20.3× (December 2022) to 476× (October 2021); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 8.5× | (38.21%) |
| FY2022 | 13.7× | (82.59%) |
| FY2021 | 78.9× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2021 | 78.9× | (82.09%) |
| Sep 2021 | 441× | — |
| Jun 2021 | 0.0× | — |
| Mar 2021 | 0.0× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ESLA Estrella Immunopharma, Inc. compare | n/m |
| PLRZ Polyrizon Ltd. compare | n/m |
| CNTX Context Therapeutics Inc. compare | n/m |
| IMMP Prima BioMed Ltd compare | n/m |
| EVAX Evaxion A/S - Sponsored ADR compare | 1.3× |
| BYSI BeyondSpring Inc. | 13.8× |
| ABVC ABVC BioPharma, Inc. compare | 19.6× |
| MCRB Seres Therapeutics, Inc. compare | 58.8× |
| CYAD Celyad SA compare | — |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)